An OMRF discovery could potentially open the door for the first drug option to treat age-related muscle weakness and atrophy.
Joan Merrill, M.D., is a recipient of the 2018 ACR Master designation, one of the highest honors members can receive.
In 1968, doctors told Greg Kindell that he had acute myeloid leukemia and he had just six weeks to live. Now he’s been cancer-free for 50 years.
Oblato, Inc., has acquired all rights from OMRF to OKN-007, an investigational drug for the treatment of a deadly form of brain cancer.
The grant will provide Bob Axtell with $2.8 million to study NMO and investigate its similarities to other autoimmune diseases, particularly MS.
Arthritis is the leading cause of disability in the U.S., but it isn’t just one disease.